biotransformation assays using hepatocytes or liver subcellular fractions, combined with extrapolation (IVIVE) models, have been proposed as an alternative to live fish bioconcentration studies. The uncertainty associated with IVIVE approaches to date has been attributed to assay protocols, model assumptions, or variability of data. An isolated perfused trout liver model that measures hepatic clearance has been proposed for validating IVIVE predictions in the absence of other confounding factors. Here, we investigated the hepatic clearances of five chemicals (pyrene, phenanthrene, 4--nonlyphenol, deltamethrin, and methoxychlor) in this model and compared measured rates to values predicted from published intrinsic clearances for validation of IVIVE models. Additionally, we varied protein concentrations in perfusates to test binding assumptions of these models. We found that measured and predicted hepatic clearances were in very good agreement (root mean squared error 16.8 mL h g) across three levels of protein binding and across a more diverse chemical space than previously studied within this system. Our results show that current IVIVE methods can reliably predict clearance rates and indicate that discrepancies from measured bioconcentration factors might be driven by other processes, such as extrahepatic biotransformation, etc., and help streamline optimization efforts to the processes that truly matter.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.est.2c02656DOI Listing

Publication Analysis

Top Keywords

hepatic clearance
8
isolated perfused
8
ivive models
8
hepatic clearances
8
ivive
5
validation methods
4
methods extrapolation
4
hepatic
4
extrapolation hepatic
4
clearance measurements
4

Similar Publications

Objective: The objective of this study was to determine the apparent intrinsic clearance (Cl) and fraction unbound in human liver microsomes (f) of 86 marketed central nervous system (CNS) drugs and to predict the in vivo hepatic blood clearance (CL).

Methods: Cl in human liver microsomes (HLM) was determined by substrate depletion, and f was determined by equilibrium dialysis. The relationship between lipophilicity (logP) and unbound intrinsic clearance (Cl) was explored using the Biopharmaceutical Drug Disposition Classification System (BDDCS) and Extended Clearance Classification System (ECCS).

View Article and Find Full Text PDF

parasites have a complex life cycle that transitions between mosquito and mammalian hosts, and undergo continuous cellular remodeling to adapt to various drastic environments. Following hepatocyte invasion, the parasite discards superfluous organelles for intracellular replication, and the remnant organelles undergo extensive branching and mature into hepatic merozoites. Autophagy is a ubiquitous eukaryotic process that permits the recycling of intracellular components.

View Article and Find Full Text PDF

Background And Objectives: Epcoritamab is a CD3xCD20 bispecific antibody approved for the treatment of adults with different types of relapsed or refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL) after ≥ 2 lines of systemic therapy. Here we report the first results from a population pharmacokinetic model-based analysis using data from 2 phase 1/2 clinical trials (EPCORE NHL-1, NCT03625037 and EPCORE NHL-3, NCT04542824) evaluating epcoritamab in patients with R/R B-NHL.

Methods: Plasma concentration-time data included 6819 quantifiable pharmacokinetic samples from 327 patients with R/R B-NHL.

View Article and Find Full Text PDF

Objectives: The use of plasma uracil measurements to detect dihydropyrimidine dehydrogenase (DPD) deficiency is one of the methods for preventing toxicities associated with fluoropyrimidines, including 5-Fluorouracil (5-FU). Unfortunately, this measurement is subject to variations, that may lead to unnecessary dosage reductions and therefore to a reduced efficacy of treatment. Recently, new factors such as hepatic and renal impairment have been proposed as also influencing uracil concentration.

View Article and Find Full Text PDF

Predictive model for HBsAg clearance rate in chronic hepatitis B patients treated with pegylated interferon α-2b for 48 weeks.

Hepatol Int

December 2024

Department of Infectious Diseases, School of Medicine, Shanghai East Hospital, Tongji University, Shanghai, China.

Background And Aims: Chronic hepatitis B (CHB) is a major global health concern. This study aims to investigate the factors influencing hepatitis B surface antigen (HBsAg) clearance in CHB patients treated with pegylated interferon α-2b (Peg-IFNα-2b) for 48 weeks and to establish a predictive model.

Methods: This analysis is based on the "OASIS" project, a prospective real-world multicenter study in China.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!